Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia 2Burkitt Lymphoma 2Triple Negative Breast Neoplasms 1Prostate Cancer Recurrent 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Blast Crisis 1

Interventions

Cytarabine 7Cyclophosphamide 7Dexamethasone 6venetoclax 4blinatumomab 4Methotrexate 4Inotuzumab Ozogamicin 4pegaspargase 3merphos 3Vincristine 3Specimen Handling 3prednylidene 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2calaspargase pegol 2azathiopurine 2auricularum 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Calcium Dobesilate 2Biopsy 2Asparaginase 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Dasatinib × Clear all
NCT05751044 2025-09-16

HEM-iSMART B

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡